Q2 2023

Filed Aug 10, 2023 · 10-Q · 41 days after period end · 0001615219-23-000061

Q2 2023 · 10-Q

Revenue—

Net Income

-$3.88M

N/M vs Q2 2022

EPS Diluted

-$11.45

N/M vs Q2 2022

Operating Income-$3,971,395N/M

Operating Cash Flowderived-$4,416,447N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	—	$0.00	$571.39K	$1.24M
Net Income	-$3.88M	-$4.72M	-$3.07M	-$1.78M
EPS Diluted	-$11.45	-$2.20	-$0.07	-$0.13

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR